MCID: NRC002
MIFTS: 55

Narcolepsy

Categories: Eye diseases, Genetic diseases, Mental diseases, Muscle diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Narcolepsy

MalaCards integrated aliases for Narcolepsy:

Name: Narcolepsy 12 73 20 43 53 36 29 54 44 15 62 70
Gelineau Syndrome 20 43 6
Narcolepsy-Cataplexy Syndrome 20 70
Cataplexy and Narcolepsy 29 6
Narcoleptic Syndrome 20 43
Paroxysmal Sleep 12 20
Narcolepsy, Without Cataplexy 12
Narcolepsy with Cataplexy 17
Gelineau's Syndrome 20

Classifications:



External Ids:

Disease Ontology 12 DOID:8986
KEGG 36 H01293
ICD9CM 34 347.0
MeSH 44 D009290
NCIt 50 C84489
SNOMED-CT 67 155059003
ICD10 32 G47.4 G47.41
UMLS 70 C0027404 C0751362

Summaries for Narcolepsy

MedlinePlus Genetics : 43 Narcolepsy is a chronic sleep disorder that disrupts the normal sleep-wake cycle. Although this condition can appear at any age, it most often begins in adolescence.Narcolepsy is characterized by excessive daytime sleepiness. Affected individuals feel tired during the day, and several times a day they may experience an overwhelming urge to sleep. "Sleep attacks" can occur at unusual times, such as during a meal or in the middle of a conversation. They last from a few seconds to a few minutes and often lead to a longer nap, after which affected individuals wake up feeling refreshed.Another common feature of narcolepsy is cataplexy, which is a sudden loss of muscle tone in response to strong emotion (such as laughing, surprise, or anger). These episodes of muscle weakness can cause an affected person to slump over or fall, which occasionally leads to injury. Episodes of cataplexy usually last just a few seconds, and they may occur from several times a day to a few times a year. Most people diagnosed with narcolepsy also have cataplexy. However, some do not, which has led researchers to distinguish two major forms of the condition: narcolepsy with cataplexy and narcolepsy without cataplexy.Narcolepsy also affects nighttime sleep. Most affected individuals have trouble sleeping for more than a few hours at night. They often experience vivid hallucinations while falling asleep (hypnogogic hallucinations) or while waking up (hypnopompic hallucinations). Affected individuals often have realistic and distressing dreams, and they may act out their dreams by moving excessively or talking in their sleep. Many people with narcolepsy also experience sleep paralysis, which is an inability to move or speak for a short period while falling asleep or awakening. The combination of hallucinations, vivid dreams, and sleep paralysis is often frightening and unpleasant for affected individuals.Some people with narcolepsy have all of the major features of the disorder, while others have only one or two. Most of the signs and symptoms persist throughout life, although episodes of cataplexy may become less frequent with age and treatment.

MalaCards based summary : Narcolepsy, also known as gelineau syndrome, is related to narcolepsy 1 and narcolepsy 2, and has symptoms including hemiplegia, excessive daytime somnolence and snoring. An important gene associated with Narcolepsy is HCRT (Hypocretin Neuropeptide Precursor), and among its related pathways/superpathways are Hematopoietic cell lineage and Rheumatoid arthritis. The drugs Sodium oxybate and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include eye, hypothalamus and cortex.

Disease Ontology : 12 A sleep disorder that involves an excessive urge to sleep at inappropriate times, such as while at work.

GARD : 20 Narcolepsy is a chronic brain disorder that involves poor control of sleep-wake cycles. People with narcolepsy have episodes of extreme daytime sleepiness and sudden, irresistible bouts of sleep (called "sleep attacks") that can occur at any time, and may last from seconds or minutes. Other signs and symptoms may include cataplexy (a sudden loss of muscle tone that makes a person go limp or unable to move); vivid dream-like images or hallucinations; and/or total paralysis just before falling asleep or after waking-up. Narcolepsy may have several causes, the most common being low levels of the neurotransmitter hypocretin (for various possible reasons). The disorder is usually sporadic but some cases are familial. There is no cure, but some symptoms can be managed with medicines and lifestyle changes.

NINDS : 53 Narcolepsy is a chronic neurological disorder caused by the brain's inability to regulate sleep-wake cycles. Many people with narcolepsy also experience uneven and interrupted sleep that can involve waking up frequently during the night.  At various times throughout the day, people with narcolepsy experience overpowering bouts of sleep. If the urge becomes overwhelming, individuals will fall asleep for periods lasting from a few seconds to several minutes. In rare cases, some people may remain asleep for an hour or longer.  In addition to excessive daytime sleepiness (EDS), people with narcolepsy experience some or all of the typical symptoms of cataplexy (the sudden loss of voluntary muscle tone), vivid hallucinations during sleep onset or upon awakening, and brief episodes of total paralysis at the beginning or end of sleep called sleep paralysis).  Because narcolepsy is often misdiagnosed as other conditions, it may take years to get the proper diagnosis. The cause of narcolepsy remains unknown.  It is likely that narcolepsy involves multiple factors interacting to cause neurological dysfunction and sleep disturbances.

KEGG : 36 Narcolepsy is a disabling sleep disorder characterized by irresistible excessive daytime sleepiness and cataplexy, a condition triggered by strong emotions leading to a sudden loss of muscle tone. Narcolepsy is a rare and mainly sporadic disorder. Familial narcolepsy accounts for less than 10% of all narcolepsy cases, and causative mutations have not been identified to date. The discovery of hypocretin-1 (HCRT) deficiency shed light on the underlying pathophysiology of the disease. The hypocretin neurotransmission system was shown to play a major role in controlling vigilance states. Because of the strong HLA association, hypocretin deficiency is believed to be caused by an autoimmune attack. It has also been reported that a missense mutation in myelin oligodendrocyte glycoprotein (MOG) is the cause of narcolepsy.

PubMed Health : 62 About narcolepsy: Narcolepsy (NAR-ko-lep-se) is a disorder that causes periods of extreme daytime sleepiness. The disorder also may cause muscle weakness. Most people who have narcolepsy have trouble sleeping at night. Some people who have the disorder fall asleep suddenly, even if they're in the middle of talking, eating, or another activity. Narcolepsy also can cause:

Wikipedia : 73 Narcolepsy is a long-term neurological disorder that involves a decreased ability to regulate sleep-wake... more...

Related Diseases for Narcolepsy

Diseases in the Narcolepsy family:

Narcolepsy 1 Narcolepsy 2
Narcolepsy 3 Narcolepsy 4
Narcolepsy 5 Narcolepsy 6
Narcolepsy 7

Diseases related to Narcolepsy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 342)
# Related Disease Score Top Affiliating Genes
1 narcolepsy 1 33.3 P2RY11 MOG HLA-DQB1 HCRT
2 narcolepsy 2 32.9 NRCLP2 HLA-DQB1 HCRT
3 idiopathic hypersomnia 32.8 HLA-DQB1 HCRT
4 hypersomnia 32.6 HLA-DQB1 HCRT
5 sleep disorder 32.5 TNF MOG HCRTR2 HCRTR1 HCRT ATXN3
6 autoimmune disease 31.2 TNF MOG HLA-DQB1 HLA-DQA1 DNMT1
7 kleine-levin hibernation syndrome 30.9 HLA-DQB1 HCRT
8 guillain-barre syndrome 30.8 TNF MOG HLA-DQB1 HLA-DQA1 HCRT
9 periodic limb movement disorder 30.7 HCRTR2 HCRT
10 acute disseminated encephalomyelitis 30.5 MOG HLA-DQB1 HLA-DQA1 HCRT
11 recurrent hypersomnia 30.5 HLA-DQB1 HCRT
12 neuritis 30.3 TNF MOG HLA-DQA1
13 neurosarcoidosis 30.3 TNF MOG
14 optic neuritis 30.3 TNF MOG HLA-DQB1 HLA-DQA1
15 cerebellar ataxia, deafness, and narcolepsy, autosomal dominant 11.8
16 narcolepsy 7 11.6
17 narcolepsy 5 11.3
18 narcolepsy 4 11.3
19 narcolepsy 6 11.2
20 narcolepsy 3 11.2
21 disseminated sclerosis with narcolepsy 10.9
22 sleep apnea 10.7
23 achalasia, familial esophageal 10.5 HLA-DQB1 HLA-DQA1
24 rohhad 10.5 HCRTR2 HCRTR1 HCRT
25 von economo's disease 10.5 HCRTR2 HCRTR1 HCRT
26 primary adrenal insufficiency 10.5 HLA-DQB1 HLA-DQA1
27 oligoarticular juvenile idiopathic arthritis 10.5 TNF HLA-DQB1 HLA-DQA1
28 beryllium disease 10.5 TNF HLA-DQB1
29 endometritis 10.5 TNF HLA-DQB1 HLA-DQA1
30 influenza 10.5
31 dermatitis herpetiformis 10.5 TNF HLA-DQB1 HLA-DQA1
32 rubella 10.5 TNF MOG HLA-DQB1 HLA-DQA1
33 chronic beryllium disease 10.5 TNF HLA-DQB1
34 rheumatic fever 10.5 TNF HLA-DQB1 HLA-DQA1
35 rheumatic heart disease 10.5 TNF HLA-DQB1 HLA-DQA1
36 primary progressive multiple sclerosis 10.5 TNF MOG HLA-DQB1
37 rem sleep behavior disorder 10.5
38 autoimmune hepatitis type 1 10.5 HLA-DQB1 HLA-DQA1
39 hematuria, benign familial 10.5 HCRTR2 HCRTR1 HCRT ATXN3
40 pediatric multiple sclerosis 10.5 MOG HLA-DQB1
41 focal epithelial hyperplasia 10.5 HLA-DQB1 HLA-DQA1
42 calcinosis 10.5 TNF HLA-DQB1 HLA-DQA1
43 toxoplasmosis 10.5 TNF HLA-DQB1 HLA-DQA1
44 podoconiosis 10.5 HLA-DQB1 HLA-DQA1
45 postpoliomyelitis syndrome 10.4 TNF HCRT
46 shrimp allergy 10.4 HLA-DQB1 HLA-DQA1
47 juvenile rheumatoid arthritis 10.4 TNF HLA-DQB1 HLA-DQA1
48 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.4
49 pemphigoid 10.4 TNF HLA-DQB1
50 restless legs syndrome 10.3

Comorbidity relations with Narcolepsy via Phenotypic Disease Network (PDN):


Hypertension, Essential Hypothyroidism

Graphical network of the top 20 diseases related to Narcolepsy:



Diseases related to Narcolepsy

Symptoms & Phenotypes for Narcolepsy

UMLS symptoms related to Narcolepsy:


hemiplegia; excessive daytime somnolence; snoring; sleep disturbances; sleeplessness; sluggishness

Drugs & Therapeutics for Narcolepsy

PubMed Health treatment related to Narcolepsy: 62

Narcolepsy has no cure. However, medicines, lifestyle changes, and other therapies can relieve many of its symptoms. Treatment for narcolepsy is based on the type of symptoms you have and how severe they are. Not all medicines and lifestyle changes work for everyone. It may take weeks to months for you and your doctor to find the best treatment .

Drugs for Narcolepsy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sodium oxybate Approved Phase 4 502-85-2 5360545
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Norepinephrine Approved Phase 4 51-41-2 439260
4 Central Nervous System Stimulants Phase 4
5
Sodium citrate Approved, Investigational Phase 3 68-04-2
6
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
7 Anesthetics, General Phase 3
8 Anesthetics, Intravenous Phase 3
9 Pharmaceutical Solutions Phase 3
10 Citrate Phase 3
11
Caffeine Approved Phase 1, Phase 2 58-08-2 2519
12
Reboxetine Approved, Experimental Phase 2 71620-89-8, 98769-81-4 123628 65856
13
Adenosine Approved, Investigational Phase 1, Phase 2 58-61-7 60961
14
Flecainide Approved, Withdrawn Phase 2 54143-55-4 3356
15
Flumazenil Approved Phase 1, Phase 2 78755-81-4 3373
16
Modafinil Approved, Investigational Phase 2 68693-11-8 4236
17
Clarithromycin Approved Phase 2 81103-11-9 84029
18
Dextroamphetamine Approved, Illicit Phase 2 51-64-9 5826
19
Amphetamine Approved, Illicit, Investigational Phase 2 300-62-9 5826 3007
20
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
21 Psychotropic Drugs Phase 2
22 GABA Modulators Phase 1, Phase 2
23 Antidepressive Agents Phase 2
24 Phosphodiesterase Inhibitors Phase 1, Phase 2
25 Caffeine citrate Phase 1, Phase 2
26 Sodium Channel Blockers Phase 2
27 Anti-Arrhythmia Agents Phase 2
28 Diuretics, Potassium Sparing Phase 2
29 Antidotes Phase 1, Phase 2
30 Protective Agents Phase 1, Phase 2
31 Dopamine Agents Phase 2
32 Neurotransmitter Agents Phase 2
33 Cytochrome P-450 CYP3A Inhibitors Phase 2
34 Anti-Bacterial Agents Phase 2
35 Antibiotics, Antitubercular Phase 2
36 Anti-Infective Agents Phase 2
37 Cytochrome P-450 Enzyme Inhibitors Phase 2
38 Dopamine Uptake Inhibitors Phase 2
39 Adrenergic Agents Phase 2
40 adderall Phase 2
41 Sympathomimetics Phase 2
42
Histamine Phosphate Phase 2 51-74-1 65513
43
Serotonin Investigational, Nutraceutical Phase 1, Phase 2 50-67-9 5202
44
Povidone Approved Phase 1 9003-39-8 131751496
45
Phenylephrine Approved Phase 1 59-42-7 6041
46
Oxymetazoline Approved, Investigational Phase 1 1491-59-4 4636
47 Anesthetics Phase 1
48 Carboxymethylcellulose Sodium Phase 1
49
Entacapone Approved, Investigational 130929-57-6 5281081
50
Carbidopa Approved 28860-95-9 34359

Interventional clinical trials:

(show top 50) (show all 100)
# Name Status NCT ID Phase Drugs
1 Does Xyrem Influence Brain Dopamine in Patients With Narcolepsy? A PET Imaging Investigation Completed NCT02637076 Phase 4 Xyrem
2 Single Center, Therapeutic Exploratory Clinical Trial to Evaluate the Safety of Sodium Oxybate (Xyrem) 500 mg/mL Oral Solution on Potential Endocrine Changes at Currently Labeled Therapeutic Dose Regimens (4.5 - 9 g/Day Divided Into Two Equal Doses) During 12 Weeks of Treatment of Cataplexy in Adult Patients With Narcolepsy. Completed NCT00345800 Phase 4 Sodium Oxybate (Xyrem)
3 A Pilot, Multiple Crossover, Randomized Block Sequence, Double-Blind, Placebo-Controlled Trial for Use of Methylphenidate for Cognitive and Behavioral Symptoms in Mild Cognitive Impairment and Dementia Completed NCT03811847 Phase 4 Methylphenidate Extended Release Oral Capsule
4 A Phase 4 Multicenter, Open-label, Single-arm Study of Safety, Tolerability, Effectiveness and Treatment Optimization in Participants Switching From Xyrem to XYWAV for the Treatment of Narcolepsy Recruiting NCT04794491 Phase 4 JZP-258
5 Solriamfetol in Binge Eating Disorder Not yet recruiting NCT04602936 Phase 4 Solriamfetol;Placebo
6 Randomized, Double-blind, Placebo and Comparator-controlled, Parallel-group, Multi-center Trial Assessing the Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy Completed NCT01638403 Phase 3 BF2.649;Vigil;palcebo
7 A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy Completed NCT02221869 Phase 3 Xyrem
8 A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy Completed NCT03030599 Phase 3 JZP-258
9 A Randomized, Double Blind Study Comparing Pitolisant (BF2.649) to Placebo in Two Parallel Groups on the Weekly Frequency of Cataplexy Attacks and Excessive Daytime Sleepiness in Narcoleptic Patients With Cataplexy. Completed NCT01800045 Phase 3 Pitolisant;Placebo
10 A 12-Month, Open-Label, Flexible-Dosage (100 to 250 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil (CEP-10953) in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder (With an Open-Ended Extension Period) Completed NCT00228553 Phase 3 Armodafinil 100 to 250 mg/day
11 Prospective, Randomized, Double-blind Study, Parallel-group, Multi-center Trial Assessing the Effects of Escalating Doses of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolepsy Completed NCT01067235 Phase 3 BF2.649;BF2.649 add on Modafinil
12 An Open-label Naturalistic Pragmatic Study to Assess the Long Term Safety of BF2.649 (Pitolisant) in the Treatment of Excessive Daytime Sleepiness (EDS) in Narcolepsy (12 Months Follow-up, Followed by a Prolonged Follow up) Completed NCT01399606 Phase 3 BF2.649
13 A Double-blind, Randomized, Placebo Controlled, Two Arm Multi-center Study to Assess the Efficacy and Safety of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension (FT218) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Subjects With Narcolepsy Completed NCT02720744 Phase 3 Sodium Oxybate;Placebo
14 Prospective, Randomized, Double-blind Study, Placebo-controlled, Parallel-group, Multi-center Trial Assessing the Effects of BF2.649 in Treatment of Excessive Daytime Sleepiness in Narcolepsy Completed NCT01067222 Phase 3 BF2.649;Modafinil;Placebo
15 A Long-Term Safety and Maintenance of Efficacy Study ofJZP-110 [(R)-2-amino-3 Phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or Obstructive Sleep Apnea Completed NCT02348632 Phase 3 JZP-110
16 A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy Completed NCT02348593 Phase 3 JZP-110;Placebo oral tablet
17 A 1 Year Open Label, Flexible Dosage Extension Study to Assess the Safety and Continued Effectiveness of PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00107848 Phase 3 Modafinil
18 A Short-term (8 Week) Open-Label Study, Followed by a Long Term Evaluation, to Assess Patient-Reported Outcomes With Armodafinil Treatment (150 to 250 mg/Day) for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00228566 Phase 3 Armodafinil
19 A 6-Month Open Label, Flexible-Dosage Study to Assess the Safety and Effectiveness of PROVIGIL (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00214968 Phase 3 Modafinil
20 Long-Term, Open-Label, Multi-Center Extension Trial of Xyrem® (Sodium Oxybate) Oral Solution for the Treatment of Narcolepsy Completed NCT00132873 Phase 3 Xyrem (sodium oxybate) oral solution
21 Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem (Sodium Oxybate) and Modafinil With Placebo in Treatment of Daytime Sleepiness in Narcolepsy Completed NCT00066170 Phase 3 Xyrem;Xyrem Placebo;Modafinil at established dose;Modafinil (Placebo)
22 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem (Sodium Oxybate) With Placebo for the Treatment of Narcolepsy Completed NCT00049803 Phase 3 sodium oxybate
23 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of PROVIGIL ® (Modafinil) Treatment (100, 200, and 400 mg/Day) in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy Completed NCT00107796 Phase 3 Modafinil
24 A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CEP-10953 (150 and 250 mg/Day) as Treatment for Adults With Excessive Sleepiness Associated With Narcolepsy Completed NCT00078377 Phase 3 Armodafinil;Armodafinil;Placebo
25 A 12-Month, Open-Label, Flexible-Dosage (100 to 250 mg/Day) Study of the Safety and Efficacy of CEP-10953 in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder (With an Open-Ended Extension Period) Completed NCT00078312 Phase 3 CEP-10953 (Armodafinil)
26 Double Blind Randomized Study to Assess the Efficacy of BF2.649 Compared to Placebo in add-on to Sodium Oxybate in the Treatment of Narcoleptic Patients With Residual Excessive Daytime Sleepiness (EDS) During 8 Weeks Completed NCT01789398 Phase 3 BF2.649
27 Open Label Study of Safety/Tolerability of Once Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Patients That Have and Have Not Been Previously Maintained on Twice-nightly Sodium Oxybate IR Recruiting NCT04451668 Phase 3 FT218
28 A Phase II Randomized, Double-blind, Double-dummy, Placebo and Comparator-controlled, Parallel Group, Multi-Center Study to Investigate the Safety and Efficacy of a Single Dose of JNJ-17216498 Administered to Subjects With Narcolepsy. Completed NCT00424931 Phase 2 JNJ-17216498;JNJ-17216498;Modafinil
29 A Randomized, Double-Blind, Placebo-Controlled, Crossover On-Road Driving Study Assessing the Effect of JZP-110 on Driving Performance in Subjects With Excessive Sleepiness Due to Narcolepsy Completed NCT02806908 Phase 2 JZP-110;Placebo
30 A Randomized Phase 2, Double Blind, Placebo-Controlled, Multi-Center Crossover Study Of PF-03654746 As A Daily Treatment For Excessive Daytime Sleepiness (EDS) Associated With Narcolepsy Completed NCT01006122 Phase 2 Placebo;PF-03654746
31 A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multi-center Study of the Safety and Efficacy of ADX-N05 in the Treatment of Excessive Daytime Sleepiness in Subjects With Narcolepsy Completed NCT01681121 Phase 2 ADX-N05;Placebo
32 A Randomized, Placebo-Controlled, Double-blind, Fixed-Dose, Multiple Cohort, Multiple Crossover, Dose-Finding Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2 Completed NCT02512588 Phase 2 BTD-001;Placebo
33 A Multi-center, Randomized, Double-blind, Placebo-controlled, 3-Week Crossover Study to Assess the Efficacy and Safety of AXS-12 in Subjects With Cataplexy and Excessive Daytime Sleepiness in Narcolepsy Completed NCT03881852 Phase 2 AXS-12 (Reboxetine);Placebo
34 A Phase II, Double-blind, Parallel-group Comparative Study 2 of TS-091 in Patients With Narcolepsy Completed NCT03267303 Phase 2 TS-091 5mg;TS-091 10mg;Placebo
35 The Effect of Caffeine on the Narcoleptic Patients Randomized Controlled Clinical Trial Completed NCT02832336 Phase 1, Phase 2 Vivarin;Fiber
36 Safety and Efficacy of THN102 on Sleepiness in Narcoleptic Patients Completed NCT02821715 Phase 2 Active comparator: Modafinil + placebo;THN102 300/3;THN102 300/27
37 A Four-week, Double-blind, Placebo-controlled, Randomized, Cross-over Study of the Safety and Efficacy of ADX-N05 in the Treatment of Excessive Daytime Sleepiness Completed NCT01485770 Phase 2 ADX-N05;Placebo
38 Clarithromycin for the Treatment of Hypersomnia Completed NCT01146600 Phase 2 Clarithromycin followed by placebo;Placebo then Clarithromycin
39 A Ten Subject, Double-Blind, Placebo-Controlled Trial of Single Day Dosing of Sublingual Flumazenil in Individuals With Primary Hypersomnia or Excessively Long Total Sleep Time and Excess Endogenous Potentiation of GABA-A Receptors Completed NCT01183312 Phase 1, Phase 2 Flumazenil
40 Antibiotic-mediated Improvements in Vigilance: Mechanisms of Action of Clarithromycin in Hypersomnia Syndromes Recruiting NCT04026958 Phase 2 Clarithromycin;Placebo
41 A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2) Recruiting NCT04096560 Phase 2 TAK-994;Placebo
42 A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy Recruiting NCT04072380 Phase 2 SUVN-G3031;Placebo
43 Informing Treatment Decisions in the Central Disorders of Hypersomnolence: A Pragmatic Clinical Trial of Modafinil Versus Amphetamines Recruiting NCT03772314 Phase 2 Modafinil;Amphetamine-Dextroamphetamine
44 Double Blind, Multicentre, Randomized, Placebo-controlled Trial to Evaluate Safety and Efficacy of Pitolisant in Children From 6 to Less Than 18 Years With Narcolepsy With/Without Cataplexy, Followed by a Prolonged Open-label Period Active, not recruiting NCT02611687 Phase 2 pitolisant;Placebo
45 A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1) Not yet recruiting NCT04820842 Phase 2 TAK-994;Placebo
46 An Open Label, Dose Escalation Study With A Double Blind Randomised Placebo Controlled Withdrawal To Examine The Effects Of The Histamine H3 Antagonist GSK189254 In Patients With Narcolepsy. Terminated NCT00366080 Phase 2 GSK189254
47 A 3-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Patients With Narcolepsy Completed NCT03748979 Phase 1 TAK-925;Placebo
48 A Randomized, Open-Label Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Single and Multiple Doses of Armodafinil (50, 100, and 150 mg/Day) in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy Completed NCT01624480 Phase 1 Armodafinil
49 A Phase 1 Study of TAK-925 to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of TAK-925 in Healthy Adult and Elderly Volunteers and Patients With Narcolepsy Completed NCT03332784 Phase 1 TAK-925;Placebo
50 Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study to Assess the Tolerability and Pharmacokinetics of APD916 Administered to Healthy Adult Subjects Completed NCT01093508 Phase 1 APD916

Search NIH Clinical Center for Narcolepsy

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Amphetamine
AMPHETAMINE ADIPATE
Amphetamine aspartate
Amphetamine Sulfate
AMPHETAMINE/DEXTROAMPHETAMINE RESIN COMPLEX
Dextroamphetamine
DEXTROAMPHETAMINE ADIPATE
Dextroamphetamine saccharate
Dextroamphetamine Sulfate
Methamphetamine
Methylphenidate
Methylphenidate Hydrochloride
modafinil
Pemoline

Cochrane evidence based reviews: narcolepsy

Genetic Tests for Narcolepsy

Genetic tests related to Narcolepsy:

# Genetic test Affiliating Genes
1 Cataplexy and Narcolepsy 29
2 Narcolepsy 29

Anatomical Context for Narcolepsy

MalaCards organs/tissues related to Narcolepsy:

40
Eye, Hypothalamus, Cortex, Amygdala, Pituitary, Brain, T Cells

Publications for Narcolepsy

Articles related to Narcolepsy:

(show top 50) (show all 4664)
# Title Authors PMID Year
1
A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. 6 54 61
10973318 2000
2
EIF3G is associated with narcolepsy across ethnicities. 6 61
25669430 2015
3
Narcolepsy in Parkinson's disease. 61 54
20518604 2010
4
Narcolepsy: autoimmunity, effector T cell activation due to infection, or T cell independent, major histocompatibility complex class II induced neuronal loss? 61 54
20403960 2010
5
Hypocretin ligand deficiency in narcolepsy: recent basic and clinical insights. 61 54
20425033 2010
6
Monoaminergic neuronal changes in orexin deficient mice. 54 61
19703479 2010
7
Reduced amygdala activity during aversive conditioning in human narcolepsy. 61 54
20373351 2010
8
Emerging treatments for narcolepsy and its related disorders. 54 61
20166851 2010
9
Hypocretin/orexin and narcolepsy: new basic and clinical insights. 54 61
19555382 2010
10
Rapid eye movement sleep behaviour disorder in patients with narcolepsy is associated with hypocretin-1 deficiency. 61 54
20129934 2010
11
Anxiety and mood disorders in narcolepsy: a case-control study. 61 54
20114128 2010
12
Body mass index-independent metabolic alterations in narcolepsy with cataplexy. 54 61
19928388 2009
13
Distribution of neurochemical abnormalities in patients with narcolepsy with cataplexy: An in vivo brain proton MR spectroscopy study. 61 54
19463917 2009
14
[Hypocretin system and narcolepsy]. 54 61
20011964 2009
15
Absence of ubiquitinated inclusions in hypocretin neurons of patients with narcolepsy. 61 54
19687452 2009
16
Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. 54 61
19725250 2009
17
Cell transplantation: a future therapy for narcolepsy? 61 54
19689312 2009
18
CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. 61 54
19238805 2009
19
IGFBP3 colocalizes with and regulates hypocretin (orexin). 54 61
19158946 2009
20
The signalling profile of recombinant human orexin-2 receptor. 61 54
18599270 2008
21
Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy. 54 61
18714784 2008
22
[Narcolepsy with cataplexy]. 61 54
18805301 2008
23
Normal levels of cerebrospinal fluid hypocretin-1 and daytime sleepiness during attacks of relapsing-remitting multiple sclerosis and monosymptomatic optic neuritis. 54 61
18505777 2008
24
Narcolepsy: immunological aspects. 61 54
18291691 2008
25
The hypocretin neurotransmission system in myotonic dystrophy type 1. 54 61
18195268 2008
26
Prevalence of HLA DQB1*0602 allele in patients with migraine. 54 61
18345414 2007
27
The hypocretin/orexin receptor: therapeutic prospective in sleep disorders. 54 61
17970638 2007
28
[Hypocretins, peptides associated with narcolepsy]. 61 54
18246936 2007
29
Review of pathophysiology and clinical management of narcolepsy in dogs. 61 54
17873267 2007
30
The hypothalamic peptidergic system, hypocretin/orexin and vigilance control. 61 54
17376528 2007
31
Isolated mediotegmental lesion causing narcolepsy and rapid eye movement sleep behaviour disorder: a case evidencing a common pathway in narcolepsy and rapid eye movement sleep behaviour disorder. 61 54
17369596 2007
32
Analysis of extended HLA haplotypes in multiple sclerosis and narcolepsy families confirms a predisposing effect for the class I region in Tasmanian MS patients. 61 54
17256150 2007
33
Neuropeptides as possible targets in sleep disorders: special emphasis on hypocretin-deficient narcolepsy. 61 54
17305553 2007
34
Hypocretin/Orexin: a molecular link between sleep, energy regulation, and pleasure. 54 61
18070844 2007
35
Narcolepsy: pathophysiology and pharmacology. 61 54
18078360 2007
36
[Hypocretins: involvement in the regulation of sleep-wakefulness cycle and pathogenesis of narcolepsy]. 61 54
17245312 2007
37
Reduced hypothalamic gray matter in narcolepsy with cataplexy. 61 54
17187022 2006
38
Narcolepsy without cataplexy: 2 subtypes based on CSF hypocretin-1/orexin-A findings. 54 61
17162990 2006
39
Narcolepsy and the hypocretin system--where motion meets emotion. 61 54
16990828 2006
40
Narcolepsy and the hypocretins. 61 54
16979425 2006
41
Sex difference in body weight gain and leptin signaling in hypocretin/orexin deficient mouse models. 54 61
16626839 2006
42
CSF versus serum leptin in narcolepsy: is there an effect of hypocretin deficiency? 54 61
16944669 2006
43
The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions. 61 54
16766052 2006
44
Detection of autoantibodies against hypocretin, hcrtrl, and hcrtr2 in narcolepsy: anti-Hcrt system antibody in narcolepsy. 61 54
16774153 2006
45
Hypocretin (orexin) deficiency predicts severe objective excessive daytime sleepiness in narcolepsy with cataplexy. 54 61
16484654 2006
46
Molecular genetics and treatment of narcolepsy. 54 61
16754256 2006
47
Hypocretins (orexins) and sleep-wake disorders. 54 61
16168936 2005
48
Narp immunostaining of human hypocretin (orexin) neurons: loss in narcolepsy. 61 54
16135770 2005
49
Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. 54 61
16247044 2005
50
Clock gene polymorphisms and narcolepsy in positive and negative HLA-DQB1*0602 patients. 61 54
16125818 2005

Variations for Narcolepsy

ClinVar genetic disease variations for Narcolepsy:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PPAN-P2RY11 , PPAN NM_020230.7(PPAN):c.190-151C>T SNV association 180725 rs1551570 GRCh37: 19:10218030-10218030
GRCh38: 19:10107354-10107354
2 P2RY11 , PPAN-P2RY11 , PPAN NM_020230.7(PPAN):c.*354A>G SNV association 180727 rs12460842 GRCh37: 19:10222195-10222195
GRCh38: 19:10111519-10111519
3 P2RY11 , EIF3G NM_003755.5(EIF3G):c.947+103C>T SNV association 180728 rs2305795 GRCh37: 19:10226052-10226052
GRCh38: 19:10115376-10115376
4 EIF3G NM_003755.5(EIF3G):c.596-260T>C SNV association 180730 rs3826784 GRCh37: 19:10227010-10227010
GRCh38: 19:10116334-10116334
5 HCRT NM_001524.1(HCRT):c.47T>G (p.Leu16Arg) SNV Pathogenic 7303 rs104894574 GRCh37: 17:40336521-40336521
GRCh38: 17:42184503-42184503

Copy number variations for Narcolepsy from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 177309 3 55147029 55255377 Insertion HCRTR2 Narcolepsy

Expression for Narcolepsy

Search GEO for disease gene expression data for Narcolepsy.

Pathways for Narcolepsy

Pathways related to Narcolepsy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.13 TNF HLA-DQB1 HLA-DQA1
2 10.77 TNF HLA-DQB1 HLA-DQA1

GO Terms for Narcolepsy

Cellular components related to Narcolepsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II protein complex GO:0042613 8.62 HLA-DQB1 HLA-DQA1

Biological processes related to Narcolepsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide signaling pathway GO:0007218 9.5 HCRTR2 HCRTR1 HCRT
2 chemical synaptic transmission GO:0007268 9.46 HCRTR2 HCRTR1 HCRT ATXN3
3 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.26 HLA-DQB1 HLA-DQA1
4 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.13 P2RY11 HCRTR2 HCRT
5 feeding behavior GO:0007631 8.8 HCRTR2 HCRTR1 HCRT

Molecular functions related to Narcolepsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 8.96 HLA-DQB1 HLA-DQA1
2 orexin receptor activity GO:0016499 8.62 HCRTR2 HCRTR1

Sources for Narcolepsy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....